Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience
Elżbieta Szczepanek, Ositadima Chukwu, Magdalena Kamińska, Hubert Wysogląd, Agnieszka Cenda, Magdalena Zawada, Małgorzata Jakóbczyk, Joanna Wącław, Tomasz Sacha
Abstract
= 0.04) groups. It suggests that a specific ELTS-adapted treatment could help to optimize treatment results. In the study population, imatinib has demonstrated sustained efficacy and an acceptable rate of late toxic effects.
Topics & Concepts
HematologyMedicineUniversity hospitalImatinibInternal medicineMyeloid leukemiaOncologyChronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesChronic Lymphocytic Leukemia Research